Showing results (111-120 of 180) with videos related to
Sort By:
Pageof 18
Archives of Toxicology|January 1, 1988
Cytosolic epoxide hydrolase in humans: development and tissue distributionG M Pacifici, A Temellini, L Giuliani, et al.Chemico-Biological Interactions|June 1, 1994
Interindividual variability of the human hepatic sulphotransferasesG M Pacifici, A Temellini, M Castiglioni, et al.Cancer|May 15, 1989
A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patientsA Nicolini, A Carpi, G Di Marco, et al.Urology|September 1, 1985
Results of radical cystectomy for primary bladder cancer. Retrospective study of more than 200 casesL Giuliani, C Giberti, G Martorana, et al.International Journal of Radiation Biology|September 13, 2006
Clastogenicity and aneuploidy in newborn and adult mice exposed to 50 Hz magnetic fieldsI Udroiu, M Cristaldi, L A Ieradi, et al.Journal of Clinical & Laboratory Immunology|May 1, 1990
Neutrophil defect associated with hairy cell leukemiaR Gavioli, S Spisani, A L Giuliani, et al.Archives of Toxicology|January 1, 1989
Valpromide is a poor inhibitor of the cytosolic epoxide hydrolaseG M Pacifici, A Temellini, L Giuliani, et al.European Urology|January 1, 1988
Hormonal pattern and testicular histology in patients with prostatic cancer after long-term treatment with a gonadotropin-releasing hormone agonist analogueC Giberti, T Barreca, G Martorana, et al.Frontiers in Pharmacology|February 17, 2018
Non-nucleotide Agonists Triggering P2X7 Receptor Activation and Pore FormationFrancesco Di Virgilio, Anna L Giuliani, Valentina Vultaggio-Poma, et al.Oncology Reports|May 25, 2011
Low activity of circadian continuous fluorodeoxyuridine (fudr) chemotherapy in poor-prognosis metastatic renal-cancerL Miglietta, L Canobbio, D Cannata, et al.Pageof 18